Cantor Fitzgerald Reiterates Neutral on CVS Health, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on CVS Health and maintained a $62 price target.
October 01, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for CVS Health, maintaining a $62 price target, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $62 price target by Cantor Fitzgerald suggests that the analyst does not foresee significant changes in CVS Health's stock price in the short term. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100